Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453503 | 0.88 | GSTO1 (0.63) | GSTO1MAPTCNR1CNR2PIK3CD | |
| SCHEMBL448977 | 0.84 | CYP2C19 (0.46) | GSTO1MAPTMEN1KMT2AALOX5AP | |
| SCHEMBL449207 | 0.81 | MCL1 (0.43) | GSTO1ALOX5APFEN1ALDH1A1CNR2 | |
| SCHEMBL30794636 | 0.81 | MCL1 (0.43) | GSTO1ALOX5APFEN1ALDH1A1CNR2 | |
| SCHEMBL3717918 | 0.73 | GAA (0.67) | GSTO1MAPTALDH1A1PIK3CDPIK3CG | |
| SCHEMBL30795667 | 0.72 | GPR52 (0.55) | MAPTALDH1A1 | |
| SCHEMBL1578844 | 0.72 | GPR52 (0.55) | MAPTALDH1A1 | |
| SCHEMBL2511779 | 0.71 | GLA (0.43) | CNR1CNR2LMNAGLACDK1 | |
| SCHEMBL30795090 | 0.71 | LMNA (0.40) | ALDH1A1MCL1GAALMNA | |
| SCHEMBL448018 | 0.71 | LMNA (0.40) | ALDH1A1MCL1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | claimed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | claimed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | claimed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-4473578-A | ACID, ESTER OR SALT DERIVATIVES OF MERCAPTO CARBAPENEMS | BEECHAM GROUP LIMITED (GB) | 1984-09-25 | — | — | US | claimed |
| US-4454069-A | Clavulanic acid salts and their preparation from the tertiary butyl amine salt | BEECHAM GROUP LIMITED (GB) | 1984-06-12 | — | — | US | claimed |
| US-4421760-A | β-Lactam antibiotic, its preparation and use | BEECHAM GROUP LIMITED (GB) | 1983-12-20 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| WO-2023085402-A1 | PEPTIDE HAVING INHIBITORY ACTIVITY ON FORMATION OF LEUKOCYTE EXTRACELLULAR TRAPS | 平橋 淳一 | 2023-05-19 | — | — | WO | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-0060077-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-09-15 | — | — | EP | disclosed |
| EP-0057565-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-08-11 | — | — | EP | disclosed |
| EP-0050927-A1 | The preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-05-05 | — | — | EP | disclosed |
| EP-0044142-A1 | Process for the preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0044170-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0043197-A1 | Beta-Lactam antibiotic, its preparation and use | BEECHAM GROUP PLC (GB) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | GSTO1 975/4885MAPT 8/4885MEN1 3189/4885 |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | KCNN3, SCN2B, SCN1B | GSTO1 1842/4885MAPT 4830/4885MEN1 3291/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | GSTO1 1334/4885MAPT 34/4885MEN1 2468/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | GSTO1 103/4885MAPT 1687/4885MEN1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.